Sign In
Buy ONVO
$2.04
+0 (+0%)
At Close: Jul 30, 2025
Will the ONVO L90's Fast Market Entry Boost NIO's Competitive Edge?
11:00am, Wednesday, 23'rd Jul 2025
NIO's ONVO sub-brand fast-tracks the L90 SUV launch, blending premium features with aggressive pricing in China's EV market.
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
08:05am, Thursday, 24'th Apr 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and developmen
VivoSim to Carry Forward Organovo 3D Bioprinting
08:05am, Wednesday, 23'rd Apr 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs,
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
08:05am, Wednesday, 02'nd Apr 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Organovo Provides Business Update
08:05am, Thursday, 27'th Mar 2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
11:25am, Tuesday, 25'th Mar 2025
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Organovo Announces Reverse Stock Split
08:05am, Wednesday, 19'th Mar 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel dise
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
07:00am, Tuesday, 11'th Mar 2025
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugebo
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
08:05am, Thursday, 06'th Mar 2025
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
08:05am, Tuesday, 25'th Feb 2025
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment a
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
08:05am, Monday, 06'th Jan 2025
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
08:05am, Wednesday, 20'th Nov 2024
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas
Nio stock poised for 42% gain on ONVO sales momentum
11:43am, Thursday, 26'th Sep 2024
Nio Inc (NYSE: NIO) opened more than 10% up on Thursday after a JPMorgan analyst issued a super bullish note in its favour. Nick Lai now sees upside in the EV stock to $8.0.
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel diseas
